Wyoming Drug Utilization Review
P & T Committee Meeting

November 8, 2018
Laramie County Community College, CCI 130
Cheyenne, Wyoming
10 am - 1 pm

AGENDA

I. Introduction and Announcements
II. Approval of minutes of August 9, 2018
III. Department of Health
   A. Pharmacy Program Manager Report
   B. Medical Director Report
   C. DUR Manager Report
IV. Old Business
   A. Suboxone
   B. Antipsychotic dose limits (including Perseris)
V. New Business
   A. PA Criteria
      1. Review existing PA criteria
         i. Cimzia (new indication and pregnancy info)
         ii. Triptans (FYI)
         iii. Aimovig (dosing and concurrent use with Botox)
         iv. Entresto
   2. New Drugs
      i. Orilissa
      ii. Mulpleta
      iii. Ilumya
      iv. Takhzyro
      v. Ajovy
      vi. Lucemyra
      vii. Kevzara
      viii. Palynziq
      ix. Olumiant
      x. Baxdela
   3. Determine need for criteria
      i. Gabapentin and Lyrica – dose limits and concurrent use
      ii. Antipsychotics – concurrent use of injectable and oral
VI. Other
   A. 2019 Draft PDL
VII. Open Comments
VIII. Executive Session

The business portion of the meeting will be from 10 am to approximately 11:30 am. (Agenda items I - VII). The executive session (item VIII) begins at approximately 11:45 am. Committee members who are unable to attend please inform Laura at lgm@uwyo.edu or 307-766-6750.